Novo Nordisk A/S Class B

As of June 30, 2026, Novo Nordisk A/S Sponsored ADR Class B carries a market capitalization of 213.75B, placing it among publicly traded companies globally. Its enterprise value stands at 228.30B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Novo Nordisk A/S Sponsored ADR Class B's next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, Novo Nordisk A/S Sponsored ADR Class B has 4.44B shares outstanding.

As of June 30, 2026, Novo Nordisk A/S Sponsored ADR Class B trades at a trailing price-to-earnings ratio of 12.04. The price-to-sales ratio is 4.25, and the price-to-book ratio stands at 6.32.

As of June 30, 2026, Novo Nordisk A/S Sponsored ADR Class B trades at an EV/EBITDA multiple of 9.22 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 4.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.51 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Novo Nordisk A/S Sponsored ADR Class B trades at an EV/FCF ratio of 30.95, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 228.30B versus a market cap of 213.75B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Novo Nordisk A/S Sponsored ADR Class B maintains a current ratio of 0.87, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 63.33, indicating elevated leverage, while an interest coverage ratio of 273.09 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Sponsored ADR Class B posted a return on equity (ROE) of 59.82, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 33.40 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 21.62, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 37.19, useful for judging operating efficiency across full business cycles. The company generates approximately 712,588.12 in revenue per employee across its workforce of 70,671.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.31 indicates how many times Novo Nordisk A/S Sponsored ADR Class B sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Sponsored ADR Class B recorded 4.94B in income tax expense. That works out to an effective tax rate of 21.72, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 22.74B, leaving 17.80B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Novo Nordisk A/S Sponsored ADR Class B's stock has declined approximately 25.13% over the past 52 weeks. The 50-day moving average sits at 42.07, while the 200-day moving average is 44.95.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Sponsored ADR Class B generated 50.36B in revenue and converted that into 17.80B in net income, yielding earnings per share of 3.99. EBITDA reached 24.76B, while operating income came in at 21.72B.

As of June 30, 2026, Novo Nordisk A/S Sponsored ADR Class B holds 6.88B in cash and equivalents against 21.42B in total debt, resulting in a net debt position of 14.62B. Total book value stands at 33.83B, with working capital of -4.65B providing operational flexibility.

Novo Nordisk A/S Sponsored ADR Class B produced 20.16B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -12.85B in capital expenditures, free cash flow totaled 7.31B - equivalent to 1.64 per share.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Sponsored ADR Class B posted a gross margin of 80.65, reflecting its pricing power and cost economics. The operating margin of 43.13 and net profit margin of 35.35 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Novo Nordisk A/S Sponsored ADR Class B paid dividends of 1.78 per share. The dividend payout ratio of 44.64 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.41, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.59, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Novo Nordisk A/S Sponsored ADR Class B shareholders.

Novo Nordisk A/S Sponsored ADR Class B's most recent stock split took place on September 20, 2023 with a 1:2 split ratio.

As of June 30, 2026, Novo Nordisk A/S Sponsored ADR Class B has an Altman Z-Score of 4.52, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.